MARC21

000	02250nam 2200337zi 4500
001	9.931903
003	CaOODSP
005	20240103081217
006	m o d f
007	cr \|n\|\|\|\|\|\|\|\|\|
008	240102e202209 oncd o f000 0 eng d
040	\|aCaOODSP\|beng\|erda\|cCaOODSP
043	\|an-cn---
086	1 \|aH14-480/2022E-PDF
245	00\|aEvaluation of Health Canada’s Blood Research and Development Program 2017-18 to 2021-22 / \|cprepared by the Office of Audit and Evaluation, Health Canada and the Public Health Agency of Canada.
246	37\|aEvaluation of the Blood Research and Development Program - September 2022
264	1\|a[Ottawa] : \|bHealth Canada and the Public Health Agency of Canada = Santé Canada et l'Agence de la santé publique du Canada, \|cSeptember 2022.
300	\|a1 online resource (iii, 12 pages) : \|bgraphs
336	\|atext\|btxt\|2rdacontent
337	\|acomputer\|bc\|2rdamedia
338	\|aonline resource\|bcr\|2rdacarrier
500	\|aIssued also in French under title: Évaluation du Programme de recherche et de développement sur le sang de Santé Canada de 2017-2018 à 2021-2022.
520	\|a"This report presents the findings of the evaluation of the Blood Research and Development Program (BR&D) for the period from 2017-18 to 2021-22. The purpose of the evaluation was to examine the impact of activities of the Canadian Blood Services funded by Health Canada under the BR&D Program in supporting the safety of Canada’s blood supply system"--Executive summary, page ii.
650	0\|aBlood\|xCollection and preservation\|zCanada\|xSafety measures\|xEvaluation.
650	0\|aBlood\|xResearch\|zCanada\|xFinance.
710	1 \|aCanada. \|bHealth Canada, \|eissuing body.
710	2 \|aPublic Health Agency of Canada, \|eissuing body.
775	08\|tÉvaluation du Programme de recherche et de développement sur le sang de Santé Canada de 2017-2018 à 2021-2022 / \|w(CaOODSP)9.931948
856	40\|qPDF\|s620 KB\|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H14-480-2022-eng.pdf
856	4 \|qHTML\|sN/A\|uhttps://www.canada.ca/en/health-canada/corporate/transparency/corporate-management-reporting/evaluation/blood-research-development-program-2017-18-2021-22.html